Chemometric software integrated with process-development microbioreactors enhances process optimization and scale-up.
The 2015 version of the the ambr systems for bioreactor process development from Sartorius Stedim Biotech (SSB) will be supplied with integrated BioPAT MODDE Software for design of experiments (DoE), powered by Umetrics, SSB announced in a Feb. 25, 2015 press release. The software will allow bioprocess scientists to implement DoE into their workflow for simpler process optimization and scale-up to larger single-use BIOSTAT pilot and manufacturing-scale bioreactors, making bioprocess development faster and more cost-effective. The software will be supplied with the ambr 15 microbioreactor system for cell-line development and early process optimization and the ambr 250 system, which is a high-throughput scale-down model for process development.
The integrated DoE software can be used to establish a design space where relevant bioprocessing conditions are varied simultaneously. Users can configure DoE experiments using work packets that are exported from the software to the ambr system, thus configuring each microbioreactor with its own DoE-defined bioprocessing parameters. The data generated from ambr, including offline analytics, is analyzed within the software to identify critical process parameters, optimize bioprocessing conditions, and define a robust design space for implementation in larger single-use BIOSTAT pilot and manufacturing-scale bioreactors. This extended DoE functionality is also available to existing ambr users.
Source: Sartorius Stedim Biotech
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.